122 related articles for article (PubMed ID: 11220651)
1. Intermediate effect markers for colorectal cancer.
Baron JA
IARC Sci Publ; 2001; 154():113-29. PubMed ID: 11220651
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers in colorectal cancer.
Owen RW
IARC Sci Publ; 2001; 154():101-11. PubMed ID: 11220650
[TBL] [Abstract][Full Text] [Related]
3. Calcium plus vitamin D alters preneoplastic features of colorectal adenomas and rectal mucosa.
Holt PR; Bresalier RS; Ma CK; Liu KF; Lipkin M; Byrd JC; Yang K
Cancer; 2006 Jan; 106(2):287-96. PubMed ID: 16353199
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor alpha distribution in rectal crypts as a biomarker of decreased colon cancer risk in patients consuming cellulose.
Hardman WE; Cameron IL; Beer WH; Speeg KV; Kadakia SC; Lang KA
Cancer Epidemiol Biomarkers Prev; 1997 Aug; 6(8):633-7. PubMed ID: 9264277
[TBL] [Abstract][Full Text] [Related]
5. Effect of aspirin on prostaglandin E2 formation and transforming growth factor alpha expression in human rectal mucosa from individuals with a history of adenomatous polyps of the colon.
Barnes CJ; Hamby-Mason RL; Hardman WE; Cameron IL; Speeg KV; Lee M
Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 1):311-5. PubMed ID: 10207634
[TBL] [Abstract][Full Text] [Related]
6. Rectal aberrant crypt foci identified using high-magnification-chromoscopic colonoscopy: biomarkers for flat and depressed neoplasia.
Hurlstone DP; Karajeh M; Sanders DS; Drew SK; Cross SS
Am J Gastroenterol; 2005 Jun; 100(6):1283-9. PubMed ID: 15929758
[TBL] [Abstract][Full Text] [Related]
7. Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial".
Stevens RG; Pretlow TP; Hurlstone DP; Giardina C; Rosenberg DW
Cancer Prev Res (Phila); 2008 Aug; 1(3):215-6; author reply 216. PubMed ID: 19138959
[No Abstract] [Full Text] [Related]
8. Chemoprevention of large bowel carcinogenesis; the role of control of cell proliferation and significance of beta-catenin-accumulated crypts as a new biomarker.
Mori H; Yamada Y; Hirose Y; Kuno T; Katayama M; Sakata K; Yoshida K; Sugie S; Hara A; Yoshimi N
Eur J Cancer Prev; 2002 Aug; 11 Suppl 2():S71-5. PubMed ID: 12570338
[TBL] [Abstract][Full Text] [Related]
9. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
[TBL] [Abstract][Full Text] [Related]
10. Aberrant crypt foci: are they intermediate endpoints of colon carcinogenesis in humans?
Gupta AK; Schoen RE
Curr Opin Gastroenterol; 2009 Jan; 25(1):59-65. PubMed ID: 19114775
[TBL] [Abstract][Full Text] [Related]
11. Mixed hyperplastic/adenomatous polyps--a collision.
Biyani DK; Skordilis K; Watson AJ
Colorectal Dis; 2008 Jan; 10(1):96-8. PubMed ID: 17441967
[No Abstract] [Full Text] [Related]
12. Early events in human colorectal carcinogenesis. Aberrant crypts and microadenoma.
Roncucci L
Ital J Gastroenterol; 1992; 24(9):498-501. PubMed ID: 1489980
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of small colorectal adenoma less than 10 mm: the KASID study.
Yoo TW; Park DI; Kim YH; Kim HS; Kim WH; Kim TI; Kim HJ; Yang SK; Byeon JS; Lee MS; Jung IK; Chung MK; Jung SA; Jeen YT; Choi JH; Choi H; Han DS; Song JS
Hepatogastroenterology; 2007 Mar; 54(74):418-21. PubMed ID: 17523287
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps.
Schoen RE; Weissfeld JL; Kuller LH; Thaete FL; Evans RW; Hayes RB; Rosen CJ
Gastroenterology; 2005 Aug; 129(2):464-75. PubMed ID: 16083703
[TBL] [Abstract][Full Text] [Related]
15. Aberrant crypt foci and beta-catenin accumulated crypts; significance and roles for colorectal carcinogenesis.
Mori H; Yamada Y; Kuno T; Hirose Y
Mutat Res; 2004 May; 566(3):191-208. PubMed ID: 15082237
[TBL] [Abstract][Full Text] [Related]
16. The promise and peril of surrogate end points in cancer research.
Schatzkin A; Gail M
Nat Rev Cancer; 2002 Jan; 2(1):19-27. PubMed ID: 11902582
[TBL] [Abstract][Full Text] [Related]
17. The case for population-based screening for colorectal cancer.
Schoen RE
Nat Rev Cancer; 2002 Jan; 2(1):65-70. PubMed ID: 11902587
[TBL] [Abstract][Full Text] [Related]
18. Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps.
Poole EM; Bigler J; Whitton J; Sibert JG; Potter JD; Ulrich CM
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):502-8. PubMed ID: 16537708
[TBL] [Abstract][Full Text] [Related]
19. The Immunohistochemical expression of endothelial cell differentiation gene-2 receptor in human colorectal adenomas.
Komuro Y; Watanabe T; Kitayama J; Yamaguchi H; Tsuno N; Nagawa H
Hepatogastroenterology; 2003; 50(54):1770-3. PubMed ID: 14696401
[TBL] [Abstract][Full Text] [Related]
20. Cell proliferation and its evaluation in the colorectal mucosa: effect of ethanol.
Seitz HK; Simanowski UA; Homann N; Waldherr R
Z Gastroenterol; 1998 Aug; 36(8):645-55. PubMed ID: 9773483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
